Cardio Diagnostics
CDIO
Market cap $6.43M

0.2100 USD

+0.0058

2.84%

At close Oct 11, 4:00 PM EDT

After hours

0.2136

+0.0036

1.71%

1 day

2.84%

5 days

-5.62%

1 month

-27.76%

3 months

-61.82%

6 months

-80.56%

Year to date

-93.14%

1 year

-21.85%

5 years

-94.50%

About: Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.

Employees: 9

Healthcare In Vitro & In Vivo Diagnostic Substances

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

14% more funds holding

Funds holding: 14 [Q1] → 16 (+2) [Q2]

0.08% more ownership

Funds ownership: 7.9% [Q1] → 7.98% (+0.08%) [Q2]

57% less capital invested

Capital invested by funds: $2.3M [Q1] → $996K (-$1.31M) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$2

852%

upside

Avg. target

$2

852%

upside

High target

$2

852%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Benchmark

Bruce Jackson

35% 1-year accuracy

17 / 49 met price target

852%upside

$2

Speculative Buy

Reiterated

27 Aug 2024

See Analyst Rankings

Financial journalist opinion

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from CMS.

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

CHICAGO--(BUSINESS WIRE)--CDIO.AI emphasizes Cardio Diagnostics' AI-first, scalable solutions for preventing, detecting and managing cardiovascular disease.

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood test, Epi+Gen CHD is now available at FMS' retail clinical location at the Meijer Supercenter in McHenry, IL.

Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois

Cardio Diagnostics Announces It's Exhibiting at the 2024 Onsite Employee Health Clinics Forum

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum.

Cardio Diagnostics Announces It's Exhibiting at the 2024 Onsite Employee Health Clinics Forum

Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit.

Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality

Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services' (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the MolDx program.

Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services' (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests

Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists' Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood tests are now available at FMS' newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois.

Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists' Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

CHICAGO--(BUSINESS WIRE)--New study finds that Cardio Diagnostics' PrecisionCHD™ test could save health insurers over $113 Million per year.

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

CHICAGO--(BUSINESS WIRE)--Exponential Health adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests marking a new era in personalized and preventive cardiac care.

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

CHICAGO--(BUSINESS WIRE)--This collaboration aims to expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.

Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

See News Rankings

Charts implemented using Lightweight Charts™